Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.

Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in binding and in signal transduction assays: calcium mobilization, inositol phosphate turnover, cAMP-responsive element (CRE), and serum-responsive element (SRE) controlled transcription, as well as arrestin mobilization. MK-677 acted as a simple agonist having an affinity of 6.5 nm and activated all signal transduction systems with similar high potency (0.2-1.4 nm). L-692,429 also displayed a very similar potency in all signaling assays (25-60 nm) but competed with a 1000-fold lower apparent affinity for ghrelin binding and surprisingly acted as a positive allosteric receptor modulator by increasing ghrelin's potency 4- to 10-fold. In contrast, the potency of GHRP-6 varied 600-fold (0.1-61 nm) depending on the signal transduction assay, and it acted as a negative allosteric modulator of ghrelin signaling. Unexpectedly, the maximal signaling efficacy for ghrelin was increased above what was observed with the hormone itself during coadministration with the nonendogenous agonists. It is concluded that agonists for the ghrelin receptor vary both in respect of their intrinsic agonist properties and in their ability to modulate ghrelin signaling. A receptor model is presented wherein ghrelin normally only activates one receptor subunit in a dimer and where the smaller nonendogenous agonists bind in the other subunit to act both as coagonists and as either neutral (MK-677), positive (L-692,429), or negative (GHRP-6) modulators of ghrelin function. It is suggested that an optimal drug candidate could be an agonist that also is a positive modulator of ghrelin signaling.

[1]  T. Schwartz,et al.  Common Structural Basis for Constitutive Activity of the Ghrelin Receptor Family* , 2004, Journal of Biological Chemistry.

[2]  W. Shimizu,et al.  Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart Failure , 2004, Circulation.

[3]  L. Prézeau,et al.  Activation mechanism of the heterodimeric GABA(B) receptor. , 2004, Biochemical pharmacology.

[4]  H. Jingami,et al.  Negative Cooperativity of Glutamate Binding in the Dimeric Metabotropic Glutamate Receptor Subtype 1* , 2004, Journal of Biological Chemistry.

[5]  L. Prézeau,et al.  The Heptahelical Domain of GABAB2 Is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABAB Receptor* , 2004, Journal of Biological Chemistry.

[6]  L. Prézeau,et al.  Closed state of both binding domains of homodimeric mGlu receptors is required for full activity , 2004, Nature Structural &Molecular Biology.

[7]  Rasmus Jorgensen,et al.  Development of a BRET2 Screening Assay Using β-Arrestin 2 Mutants , 2004 .

[8]  G. Frost,et al.  Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  Didier Rognan,et al.  Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.

[10]  Robert J. Lefkowitz,et al.  beta-arrestins: traffic cops of cell signaling. , 2004, Current opinion in cell biology.

[11]  C. Zetterberg,et al.  The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture , 2004, Journal of the American Geriatrics Society.

[12]  T. Schwartz,et al.  Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. , 2004, Trends in pharmacological sciences.

[13]  Peeters Tl.  Central and peripheral mechanisms by which ghrelin regulates gut motility. , 2003 .

[14]  T. Schwartz,et al.  High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist. , 2003, Molecular endocrinology.

[15]  D. Cummings,et al.  Ghrelin-leptin tango in body-weight regulation. , 2003, Gastroenterology.

[16]  T. Schwartz,et al.  Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.

[17]  S. Lazareno,et al.  Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. , 2002, Molecular pharmacology.

[18]  M. Nakazato,et al.  Ghrelin: a novel peptide for growth hormone release and feeding regulation , 2002, Current opinion in clinical nutrition and metabolic care.

[19]  R. Silverstein,et al.  CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart , 2002, Circulation research.

[20]  T. Schwartz,et al.  NOVEL METHOD FOR THE STUDY OF RECEPTOR Ca2+ SIGNALLING EXEMPLIFIED BY THE NK1 RECEPTOR , 2002, Journal of receptor and signal transduction research.

[21]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  L. Singh,et al.  Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: the involvement of protein kinases A and C. , 2001, Diabetes.

[23]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[24]  J. Saldanha,et al.  Multiple allosteric sites on muscarinic receptors. , 2001, Life sciences.

[25]  K. Kangawa,et al.  Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor , 2001, Trends in Endocrinology & Metabolism.

[26]  T. Schnitzer,et al.  Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  S. Nakanishi,et al.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.

[28]  S. Lazareno,et al.  Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. , 2000, Molecular pharmacology.

[29]  S. Lazareno,et al.  Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. , 2000, Molecular pharmacology.

[30]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[31]  Hansen,et al.  Growth hormone secretagogues: recent advances and applications. , 1999, Drug discovery today.

[32]  S. Lazareno,et al.  Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. , 1999, Molecular pharmacology.

[33]  Roy G. Smith,et al.  Peptidomimetic regulation of growth hormone secretion. , 1997, Endocrine reviews.

[34]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[35]  D. Johnston,et al.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Means,et al.  Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression , 1994, Molecular and cellular biology.

[37]  S. Pong,et al.  A nonpeptidyl growth hormone secretagogue. , 1993, Science.

[38]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[39]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[40]  F. Momany,et al.  Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. , 1980, Endocrinology.

[41]  H Gobind Khorana,et al.  Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.

[42]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[43]  T. Schwartz,et al.  Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. , 1998, Molecular pharmacology.

[44]  D. Underwood,et al.  Structural Requirements for the Activation of the Human Growth Hormone Secretagogue Receptor by Peptide and Nonpeptide Secretagogues , 1997 .